Betta Pharmaceuticals

Reprogenix is a pioneering medical technology company specializing in regenerative stem cell medicine. It initially focused on stem cell therapy for diabetes and has since expanded its scope to develop advanced biomedical solutions for various disease areas. The company leverages proprietary human pluripotent stem cell technology to create innovative, regenerative treatments.

Gaowei Medicine is a drug discovery platform for developing new drugs for key intractable diseases such as cancer and neurological diseases.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.

CentryMed is a biotechnology company specializing in the development of antibody drugs for the treatment of tumors and autoimmune diseases. It has created a proprietary dual-antibody platform and constructed its own human dAb libraries, which are protected by independent intellectual property rights. This innovative approach addresses critical issues related to drug efficacy and the side effects commonly associated with antibody therapies. As of 2021, CentryMed has successfully developed over 20 unique and differentiated antibody drugs aimed at targeting various solid tumors and different stages of immune diseases, thereby addressing significant clinical and patient needs.

Capio Biosciences is a biotechnology company dedicated to advancing oncology diagnostics to enhance patient care and outcomes. The company is developing an innovative platform known as CapioCyte™, which focuses on the capture of circulating tumor cells (CTCs) from whole blood. Utilizing a unique combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte™ offers significantly improved sensitivity for capturing CTCs compared to existing technologies. This platform not only facilitates the enrichment of CTCs for further molecular analysis, including FISH, RNA-Seq, and NGS, but also holds promise for future applications in clinical patient management. Through its personalized treatment therapies, Capio Biosciences aims to assist healthcare providers in effectively managing cancer treatment by enabling the removal of cancer cells from patients' bodies via liquid biopsy techniques.

Hangzhou DAC Biotech Co., Ltd., established in 2012 and headquartered in Hangzhou, China, specializes in the development of cancer treatment drugs. The company offers an antibody-drug conjugate (ADC) platform featuring over 50 intelligent linkers for site-specific conjugation and five types of high-activity small molecule compounds with varied mechanisms. Additionally, DAC Biotech provides advanced technologies for antibody discovery, engineering transformation, and production process optimization. Their services include comprehensive ADC drug evaluation in vivo and in vitro, drug structure confirmation, and analytical method development and verification.

Xcovery LLC is a biopharmaceutical company based in Palm Beach Gardens, Florida, founded in 2006. It specializes in the development of targeted oncology therapies designed to address various advanced tumors. The company is known for its lead compound, X-396, a small molecule that inhibits anaplastic lymphoma kinase, along with other kinase inhibitors targeting MET and PI3K/mTOR pathways. Xcovery aims to create low-toxicity oral drugs that facilitate continuous therapy without the need for dosing interruptions, thereby enhancing treatment efficacy and safety for cancer patients. This approach allows for a broader therapeutic window and the potential for combination therapies without the toxicity associated with current treatments. The leadership team includes experienced professionals from notable biotech backgrounds, contributing to the company's innovative research and development efforts in oncology.